Queen's University at Kingston

NIH launches precision medicine trial, myeloMATCH, to test new treatment combinations for AML and MDS, aiming to accelerate tailored treatments through rapid genetic testing and targeted drug combinations.

NIH's myeloMATCH trial tests precision medicine treatments for AML and MDS, aiming to accelerate tailored cancer therapies through genetic testing and targeted drug combinations.

MyeloMATCH, a precision-medicine initiative sponsored by the National Cancer Institute, aims to improve survival rates for acute myeloid leukemia and myelodysplastic syndrome through a coordinated, multisite clinical trial. Participants are screened for specific biomarkers and assigned to substudies targeting their genetic or molecular characteristics, with rapid diagnostic testing and potential for ongoing trial eligibility.

MyeloMATCH, a precision-medicine initiative, aims to improve survival rates for acute myeloid leukemia and myelodysplastic syndrome by conducting multiple clinical substudies based on genetic and molecular characteristics. It offers rapid diagnostic testing and is open to patients aged 18 and over, with ongoing substudies focusing on high-risk acute myeloid leukemia and FLT3 gene mutations. The initiative seeks to create a comprehensive pipeline for personalized treatment.

Desai Sethi Urology Institute researchers found that prostate cancer patients with the adrenal-permissive HSD3B1 allele had better survival outcomes when treated with ADT plus enzalutamide or ADT plus nonsteroidal antiandrogen, reversing poor genetic outcomes.